PROCEPT BioRobotics (NasdaqGM:PRCT) 2026 Investor Day February 26, 2026 08:00 AM ET Company ParticipantsBarry Templin - EVP and CTOKevin Waters - EVP and CFOLarry Wood - CEOMatt Bacso - VP of Investor Relations and Business OperationsNathan Treybeck - Equity Research VPPooja Sharma - Chief Marketing and Strategy OfficerConference Call ParticipantsBrandon Vazquez - Research AnalystChris Pasquale - Partner and Senior Analyst of Medical Devices and SuppliesJosh Jennings - Managing Director and Senior AnalystSt ...

Welcome to 2026 Analyst Day Matt Bacso VP, Investor Relations © 2026 PROCEPT BioRobotics Corporation. All Rights Reserved. 1 This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk. Exchange Commission ("SEC"), including the Ann ...

Financial Performance & Guidance - PROCEPT BioRobotics reported Q1 2024 global revenue of $445 million, an 83% year-over-year increase [22] - International revenue in Q1 2024 reached $43 million, a 65% year-over-year increase [22] - The U S installed base grew to 354 systems, an 84% year-over-year increase [22] - U S handpiece sales reached 6800, a 100% year-over-year increase [22] - The company projects total revenue for 2024 to be approximately $2135 million, representing a 57% year-over-year growth [26] - The company anticipates a gross margin of approximately 58% to 59% for 2024 [26] - Adjusted EBITDA loss is projected to be approximately $70 million for 2024 [26] - As of March 31, 2024, the company had a total cash and cash equivalents balance of $226 million and a debt balance of $52 million [27] Commercial Strategy & Market Expansion - The company aims to convert all resective BPH hospital-based procedures to Aquablation Therapy [39] - The company reports that over 95% of U S covered lives are now under signed majority IDN contracts [43] - Aquablation Therapy cases at Georgia Urology have increased 95x since 2019 [67] Prostate Cancer Research & Development - Approximately 1/3 of men with BPH also have prostate cancer, representing 300000 diagnoses per year [89] - Initial Aquablation impressions for prostate cancer show promise, with real-time imaging and surgeon confidence [113, 114] - Early results from a study (n=5) show 0% incontinence and 0% erectile dysfunction, as well as 0% actionable disease and 0% residual tumor on MRI [138, 148]